Type to search




Antengene is a global biopharmaceutical company focused on innovative oncology therapies. Our vision is to treat patients beyond borders and transform their lives by discovering, developing, commercializing and manufacturing the most advanced therapies in the world.

On November 20, 2020, we were successfully listed in the Hong Kong Stock Exchange (SEHK:6996.HK), and became one of the Hong Kong-listed biopharmaceutical companies with the shortest listing process.

Since entering operation in April 2017, we have built a highly differentiated and synergistic pipeline of 12 drug assets, including six clinical stage assets which we in-licensed from Karyopharm, Celgene and AstraZeneca; and six preclinical assets that are largely inhouse discovered. We have planned and already initiated 28 clinical trials in Korea, Australia, and China, including 5 registrational clinical trials ongoing in China.

Our core product, ATG-010 (selinexor, XPO1 inhibitor), is the first and only approved selective inhibitor of nuclear export, which has already been launched in the U.S. and Israel for the treatment of multiple myeloma and diffuse large B-cell lymphoma. Antengene obtained exclusive rights for the development and commercialization of ATG-010 (selinexor) in 17 APAC countries and regions and submitted NDAs for ATG-010 (selinexor) in five APAC markets.

Taking hematologic malignancy as one of our core therapeutic areas, we have built a management team with a global background and strong track records in the clinical development and commercialization of therapies, including REVLIMID®, a multi-million dollar oncology product, and POMALYST®, one of the best-selling oncology products worldwide.

Associated People